Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Gene Mutation”

62 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 62 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07285148
What this trial is testing

Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerEGFR MutationMetastatic Lung Cancer+1 more
Beijing Pearl Biotechnology Limited Liability Company 253
Early research (Phase 1)Ended earlyNCT01611675
What this trial is testing

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Who this might be right for
Melanoma
Massachusetts General Hospital 3
Testing effectiveness (Phase 2)Looking for participantsNCT06109558
What this trial is testing

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Who this might be right for
Non Small Cell Lung CancerRET Gene MutationMET Amplification+1 more
Hunan Province Tumor Hospital 120
Testing effectiveness (Phase 2)Ended earlyNCT04030429
What this trial is testing

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

Who this might be right for
Endometrial Cancer Recurrent
National Cheng-Kung University Hospital 40
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Early research (Phase 1)UnknownNCT04228406
What this trial is testing

Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161

Who this might be right for
Solid TumorC-Met Mutation-Related Tumors
Fujian Cosunter Pharmaceutical Co. Ltd 62
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06644313
What this trial is testing

Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Potentially Resectable MET-altered Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 31
Testing effectiveness (Phase 2)UnknownNCT03693339
What this trial is testing

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

Who this might be right for
CancerLung Cancer MetastaticMET Gene Mutation
Asan Medical Center 27
Early research (Phase 1)Study completedNCT01531361
What this trial is testing

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Who this might be right for
Advanced Malignant NeoplasmBRAF Gene MutationMetastatic Malignant Neoplasm+2 more
M.D. Anderson Cancer Center 46
Testing effectiveness (Phase 2)Study completedNCT01982955
What this trial is testing

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Who this might be right for
Non-small Cell Lung Cancer
Merck KGaA, Darmstadt, Germany 88
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT02499614
What this trial is testing

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fondazione Ricerca Traslazionale 80
Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Large-scale testing (Phase 3)Looking for participantsNCT06908993
What this trial is testing

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Who this might be right for
Advanced Non Small Cell Lung CancerMET Exon 14 Mutation
Intergroupe Francophone de Cancerologie Thoracique 133
Large-scale testing (Phase 3)Looking for participantsNCT05989542
What this trial is testing

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

Who this might be right for
Non-small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company 136
Large-scale testing (Phase 3)Looking for participantsNCT05722886
What this trial is testing

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Who this might be right for
Haematological MalignancySolid Tumour
Cancer Research UK 825
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Testing effectiveness (Phase 2)UnknownNCT02897479
What this trial is testing

A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Who this might be right for
Lung Sarcomatoid Carcinoma
Hutchison Medipharma Limited 76
Testing effectiveness (Phase 2)Looking for participantsNCT04270591
What this trial is testing

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Who this might be right for
C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd. 183
Load More Results